Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 306

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 306
---
 activities204,051 180,375 Net increase (decrease) in cash, cash equivalents and restricted cash13,043 (2,772)Cash, cash equivalents and restricted cash at beginning of period38,750 39,483 Cash, cash equivalents and restricted cash at end of period$51,793 $36,711 Supplemental disclosure of non-cash investing and financing activities:Conversion of convertible preferred stock into common stock upon closing of initial public offering$330,368 $— Offering costs transferred to additional paid in capital 4,265—Deferred offering costs in accrued expenses—851Reconciliation of cash, cash equivalents and restricted cash:Cash and cash equivalents$50,831 $35,749 Restricted cash962 962 Total cash, cash equivalents, and restricted cash$51,793 $36,711 The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-6

SIONNA THERAPEUTICS, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

(Unaudited)

1. Nature of the Business 

Organization Sionna Therapeutics, Inc. (the “Company”), formerly known as Sling Therapeutics, Inc., was incorporated in Delaware in August 2019 and is headquartered in Waltham, Massachusetts. The Company is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Risks and Uncertainties The Company is subject to a number of risks common to other companies in the biotechnology industry, including but not limited to, development by competitors of new technological innovations, risks of failure of preclinical studies and clinical trials, development and manufacturing of product candidates, obtaining regulatory approval for product candidates, competition from substitute products, the need to successfully commercialize and gain market acceptance of its product candidates, protection of proprietary technology, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third party organizations compliance with government regulations, and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive clinical testing and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities